# Atreca

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atreca

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.atreca.com
- Total disclosed funding: $208M
- Latest round: Series C (Sep 5, 2018)
- Investors on record: 11

## About

Atreca, Inc. is a biotechnology company specializing in the discovery of therapeutics and diagnostics through innovative antibody technology. Their focus lies in harnessing the power of the immune response to develop targeted treatments for cancer and other diseases.Founded in 2011, Atreca, Inc. operates out of Redwood City, US. The company utilizes a unique approach to identify and develop antibodies targeting specific diseases. The founders, Jonathan Woo and Tito Serafini, have backgrounds in biotechnology and pharmaceuticals. The company went public in June 2019, raising USD 124.95 mn in an IPO by selling 7.35 million shares at USD 17 each. They have completed a total of 8 deals.Atreca, Inc. offers a range of innovative biopharmaceutical products focusing on the development of immune-based therapeutics. Their core services include proprietary antibody discovery platforms designed to identify effective treatments for cancer and autoimmune diseases. The company’s solutions cater to various markets, particularly in the US and Europe, where the demand for advanced therapeutic options is increasing.In 2022, Atreca, Inc. reported an EBITDA of USD -90.84 mn, indicating ongoing investments in research and development to support their therapeutic initiatives.Atreca, Inc. plans to expand its product line with new antibody therapeutics currently under development, with anticipated launches in the next few years. The company aims to broaden its market presence in Europe and Asia by 2025. The recent IPO funding of USD 124.95 mn will be utilized to accelerate the development of their pipeline products and enhance research capabilities.

## Funding rounds

- Series C, Sep 5, 2018, $125M — Aisling Capital, Tekla Capital Management, Wellington Management, Redmile Group, EcoR1 Capital, Cormorant Asset Management, Boxer Capital, Samsara BioCapital
- Series B, Aug 10, 2017, $35M — Wellington Management, Cormorant Asset Management
- Series A, Aug 21, 2015, $48M — GlaxoSmithKline, Mission Bay Capital, Bill & Melinda Gates Foundation

## Investors

- GlaxoSmithKline — Series A
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series A
- Bill & Melinda Gates Foundation — Series A
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series C